{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:36:34Z","timestamp":1782484594265,"version":"3.54.5"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Subst\ufffdAbuse"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Gabapentin is widely used in the United States for a number of off-label indications, often as an alternative to opioid therapy. Increasing evidence has emerged suggesting that gabapentin may not be as benign as once thought and may be associated with substance abuse in concert with opioids. With concerns for safety mounting, it is prudent to examine the efficacy of gabapentin across its many uses to understand the risk-benefit balance. Reviews on off-label indications such as migraine, fibromyalgia, mental illness, and substance dependence have found modest to no effect on relevant clinical outcomes. This high-quality evidence has often been overshadowed by uncontrolled studies and limited case reports. Furthermore, the involvement of gabapentin in questionable marketing schemes further calls its use into question. Overall, clinicians should exercise rigorous appraisal of the available evidence for a given indication, and researchers should conduct larger, higher-quality studies to better assess the efficacy of gabapentin for many of its off-label uses.<\/jats:p>","DOI":"10.1177\/1178221818801311","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T02:17:22Z","timestamp":1537755442000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":47,"title":["Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-7005","authenticated-orcid":false,"given":"Alyssa M","family":"Peckham","sequence":"first","affiliation":[{"name":"School of Pharmacy, Northeastern University, Boston, MA, USA"},{"name":"Substance Use Disorders Initiative, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk E","family":"Evoy","sequence":"additional","affiliation":[{"name":"College of Pharmacy, The University of Texas at Austin, Austin, TX, USA"},{"name":"School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA"},{"name":"Southeast Clinic, University Health System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Ochs","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, University of New England, Portland, ME, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-2042","authenticated-orcid":false,"given":"Jordan R","family":"Covvey","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical, Administrative and Social Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,23]]},"reference":[{"key":"bibr1-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"bibr2-1178221818801311","doi-asserted-by":"publisher","DOI":"10.3821\/145.6.cpj280"},{"key":"bibr3-1178221818801311","first-page":"266","volume":"8","author":"Hamer AM","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"bibr4-1178221818801311","unstructured":"Quintiles IMS Institute. Medicines use and spending in the U.S: a review of 2016 and outlook to 2021. https:\/\/structurecms-staging-psyclone.netdna-ssl.com\/client_assets\/dwonk\/media\/attachments\/590c\/6aa0\/6970\/2d2d\/4182\/0000\/590c6aa069702d2d41820000.pdf?1493985952. Published 2017. Accessed February 2, 2018."},{"key":"bibr5-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"bibr6-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"bibr7-1178221818801311","unstructured":"Lexi-Drugs. Gabapentin. http:\/\/online.lexi.com. Accessed May 3, 2018."},{"key":"bibr8-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0595-1"},{"key":"bibr9-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402801011"},{"key":"bibr10-1178221818801311","unstructured":"Crane L. Rise and fall of gabapentin: from wonder drug to illicit substance in just 50 years. Chemistry World. Podcast. 2016. https:\/\/www.chemistryworld.com\/podcasts\/gabapentin\/1017577.article."},{"key":"bibr11-1178221818801311","unstructured":"Medicines.org.au. Product information: NEURONTIN\u00ae (gabapentin). 2018. http:\/\/www.medicines.org.au\/files\/pfpneura.pdf."},{"key":"bibr12-1178221818801311","unstructured":"Electronic Medicines Compendium. Neurontin 100mg hard capsules. 2017. https:\/\/www.medicines.org.uk\/emc\/product\/158\/smpc."},{"key":"bibr13-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12223"},{"key":"bibr14-1178221818801311","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216080-00004"},{"key":"bibr15-1178221818801311","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2003.9.6.559"},{"key":"bibr16-1178221818801311","first-page":"CD008183","volume":"5","author":"Straube S","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr17-1178221818801311","first-page":"CD010609","volume":"6","author":"Linde M","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr18-1178221818801311","first-page":"CD001415","volume":"7","author":"Al-Bachari S","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr19-1178221818801311","first-page":"CD012188","volume":"1","author":"Cooper TE","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr20-1178221818801311","first-page":"CD007938","volume":"6","author":"Wiffen PJ","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr21-1178221818801311","volume":"17","author":"Berlin RK","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"bibr22-1178221818801311","first-page":"CD008544","volume":"2","author":"Pani PP","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr23-1178221818801311","first-page":"CD006754","author":"Minozzi S","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr24-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014381"},{"key":"bibr25-1178221818801311","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00316"},{"key":"bibr26-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002369"},{"key":"bibr27-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9230"},{"key":"bibr28-1178221818801311","doi-asserted-by":"publisher","DOI":"10.5539\/gjhs.v5n6p126"},{"key":"bibr29-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e3182a7c073"},{"key":"bibr30-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199704000-00006"},{"key":"bibr31-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.25202"},{"key":"bibr32-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.10.1573"},{"key":"bibr33-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1159\/000072882"},{"key":"bibr34-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1081\/JDI-120039823"},{"key":"bibr35-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-009-0361-3"},{"key":"bibr36-1178221818801311","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.152417"},{"key":"bibr37-1178221818801311","unstructured":"US Department of Veterans Affairs, Department of Defense. Management of substance use disorder. https:\/\/www.healthquality.va.gov\/guidelines\/mh\/sud\/. Published 2015. Accessed October 5, 2018."},{"key":"bibr38-1178221818801311","doi-asserted-by":"publisher","DOI":"10.4158\/EP171828.PS"},{"key":"bibr39-1178221818801311","unstructured":"Arbor Pharmaceuticals LLC. Horziant\u00ae prescribing information. https:\/\/www.horizant.com\/assets\/docs\/Horizant_PrescribingInformation.pdf. Published 2016. Accessed September 5, 2018."},{"key":"bibr40-1178221818801311","first-page":"36","volume":"38","author":"Drug maker to pay $430 million in fines, civil damages","year":"2004","journal-title":"FDA Consum"},{"key":"bibr41-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00929.x"},{"key":"bibr42-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411173312007"},{"key":"bibr43-1178221818801311","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00008"},{"key":"bibr44-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0370"},{"key":"bibr45-1178221818801311","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181ca404e"},{"key":"bibr46-1178221818801311","unstructured":"Longstreth A. Pfizer agrees to $190 million settlement over generic Neurontin. Reuters. https:\/\/www.reuters.com\/article\/us-usa-antitrust-pfizer\/pfizer-agrees-to-190-million-settlement-over-generic-neurontin-idUSBREA3K17420140421. Published April 21, 2014. Accessed February 4, 2018."},{"key":"bibr47-1178221818801311","unstructured":"Stempel J. Pfizer to pay $325 million in Neurontin settlement. Reuters. https:\/\/www.reuters.com\/article\/us-pfizer-neurontin-settlement\/pfizer-to-pay-325-million-in-neurontin-settlement-idUSKBN0ED1IS20140602. Published June 2, 2014. Accessed February 2, 2018."}],"container-title":["Substance Abuse: Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1178221818801311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1178221818801311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1178221818801311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:29:11Z","timestamp":1777692551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1178221818801311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":47,"alternative-id":["10.1177\/1178221818801311"],"URL":"https:\/\/doi.org\/10.1177\/1178221818801311","relation":{},"ISSN":["1178-2218","1178-2218"],"issn-type":[{"value":"1178-2218","type":"print"},{"value":"1178-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"article-number":"1178221818801311"}}